膝关节骨关节炎患者长期非手术治疗与全膝关节置换术相比9年随访生存率较低:韩国全国队列生存分析
该研究基于韩国全国队列,比较2007至2009年膝关节骨关节炎患者中行全膝关节置换术组(N=2,228)与非手术药物治疗组(N=76,430)的9年随访生存率。结果显示,调整基线差异后,全膝关节置换术组调整后死亡风险显著低于非手术药物治疗组(调整后HR 0.78,95%CI 0.68-0.9),且药物持有率与总体死亡及心血管死亡呈剂量反应关系。
要点
- 全膝关节置换术组9年随访调整后死亡风险显著低于非手术药物治疗组(调整后HR 0.78,95%CI 0.68-0.9)。
- 药物持有率与总体死亡(调整后HR 1.02;95%CI 1.01-1.04)及心血管死亡(调整后SHR 1.03;95%CI 1.01-1.05)呈剂量反应关系。
- 年龄>75岁、高血压、缺血性心脏病患者中全膝关节置换术的保护性生存效应更强。
核心结论
- 调整基线差异后,全膝关节置换术组9年平均随访生存率优于非手术药物治疗组。
- 总体死亡包括心血管死亡的调整后死亡率在药物组更高,并呈剂量反应关系。
- 全膝关节置换术对年龄>75岁、高血压或缺血性心脏病患者的总体或心血管死亡保护效应更高。
研究设计与样本
- 研究纳入2007至2009年膝关节骨关节炎患者,分为全膝关节置换术组(N=2,228)和非手术药物治疗组(N=76,430),随访长达9年。
- 采用Cox比例风险回归和Fine and Gray分析分别计算风险比(HR)和亚分布风险比(SHR)。
- 证据等级为III级。
主要发现
- 全膝关节置换术组调整后死亡风险显著低于非手术药物治疗组(调整后HR 0.78,95%CI 0.68-0.9)。
- 药物持有率与总体死亡(调整后HR 1.02;95%CI 1.01-1.04)及心血管死亡(调整后SHR 1.03;95%CI 1.01-1.05)存在剂量反应关系。
- 年龄>75岁患者中全膝关节置换术对总体死亡(交互作用P=0.04)和心血管死亡(交互作用P=0.009)的保护效应更强。
- 高血压患者中全膝关节置换术对总体死亡的保护效应更强(交互作用P=0.006)。
- 缺血性心脏病患者中全膝关节置换术对心血管死亡的保护效应更强(交互作用P=0.009)。
关键数值与推荐
- 全膝关节置换术组与非手术药物治疗组比较:调整后HR 0.78(95%CI 0.68-0.9),全膝关节置换术组死亡风险更低。
- 药物持有率与总体死亡:调整后HR 1.02(95%CI 1.01-1.04)。
- 药物持有率与心血管死亡:调整后SHR 1.03(95%CI 1.01-1.05)。
- 年龄>75岁交互作用:总体死亡P=0.04,心血管死亡P=0.009。
- 高血压交互作用:总体死亡P=0.006;缺血性心脏病交互作用:心血管死亡P=0.009。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total knee arthroplasty (TKA) and medications are both considered as a treatment for knee osteoarthritis. However, the impact of the TKA on long-term survival remains controversial. This study aimed to compare 9-year follow-up survival between a TKA group with a nonoperative medication group. METHODS: From 2007 to 2009, knee osteoarthritis patients were divided into TKA (N = 2,228) and nonoperative medication (N = 76,430) groups, and followed for up to 9 years. The hazard ratio (HR) and subdistribution HR (SHR) were derived from Cox proportional hazards regressions and Fine and Gray analyses, respectively. RESULTS: The TKA group had a significantly lower adjusted mortality rate (adjusted HR , 0.78, 95% confidence interval [CI], 0.68-0.9) than the nonoperative medication group. Dose-response relationship between medication possession ratio and mortalities for overall (adjusted HR , 1.02; 95% CI, 1.01-1.04) and cardiovascular (CV) death (adjusted SHR, 1.03; 95% CI, 1.01-1.05) was also found. Also, there were significant interactions that indicate stronger protective survival effects of the TKA in several covariates: age >75 years (P = .04 for overall; P = .009 for CV), hypertension (P = .006 for overall), and ischemic heart disease (P = .009 for CV). CONCLUSIONS: This study suggests that TKA patients had better mean 9-year follow-up survival than the nonoperative medication group after adjusting for baseline differences. For overall death, including CV death, adjusted mortality rates were higher in the medication group and showed a dose-response relationship. Specifically, the protective effect of the TKA for overall or CV deaths was found to be higher for age >75, hypertension, or ischemic heart disease patients. LEVEL OF EVIDENCE: III.
引用
- Han H, Ro DH, Won S, et al. Long-Term Nonoperative Management is Associated With Lower Mean 9-Year Follow-Up Survival Compared to Total Knee Arthroplasty in Knee Osteoarthritis Patients-Survival Analysis of a Nationwide South Korean Cohort. J Arthroplasty. 2023. PMID: 36764402. doi:10.1016/j.arth.2023.01.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。